Le Lézard
Classified in: Health
Subjects: BFA, CPN, AVO

Rishi Kumar Determined To Oppose Big Money In Politics


SARATOGA, Calif., Jan. 29, 2020 /PRNewswire/ -- Democratic candidate for U.S Congress CA-18 Rishi Kumar* issued this statement ahead of the California Primary:

"I am running for Congress to represent the people's interests, not special interests. I believe in making fearless people-centric choices to address pressing community challenges. As your congressman, I will never accept PAC money or special interest group money."

Former Saratoga mayor Stan Bogosian endorses Rishi Kumar. "Rishi gets things done. While serving on the Saratoga City Council, Rishi successfully led the effort to stop repeated attempts by the San Jose Water Company to impose predatory rate increases. He will apply the same tenacity to rein in the outrageous price increases of Big Pharma. Unlike his opponent Anna Eshoo, Rishi does NOT accept contributions from Big Pharma or any other Special Interest Groups."

Here's what people have said about Anna Eshoo:
"Rep. Anna Eshoo, House Health Subcommittee Chair, has taken more pharmaceutical money than any other representative. She has sponsored legislation backed by the pharmaceutical interests funding her campaigns...(Eshoo has given) pharmaceutical companies 12-year exclusivity periods for biologic drugs, beyond the length of their patents, to protect them from competition by the generic drug industry."-- Donald Shaw, Money-in-politics reporter, co-founder of Sludge Magazine 

"Does it make sense (for Eshoo) to support a bill that sustains high drug prices, stifles innovation, and reduces our patients' access to life saving drugs?"-- The Mercury News (op-ed) 

"A scathing report by the Federal Trade Commission warned that the Eshoo legislation would ensure sky-high drug prices and stifle innovation on the most promising frontier of medical research."-- The San Francisco Chronicle

"Anna Eshoo's record on drug prices is terrible, and the reason why is obvious. She's taken enormous sums of money from drug corporations, and she does their bidding in Washington. Eshoo's name has for years been conspicuously absent from important pieces of legislation that could lower drug prices."-- David Mitchell, founder of Patients For Affordable Drugs Action 

Rishi Kumar will never accept PAC money or Special Interest Group money.
*Rishi Kumar, a progressive capitalist, is running for U.S Congress from Silicon Valley CA-18, challenging Rep. Anna Eshoo in the March 3rd, 2020 open top-2 primary election. Rishi is a hi-tech executive, councilmember of Saratoga, CA, and executive board member of the California Democratic Party (AD28).

 

Campaign slogan - "Your interests, Not Special Interests." As an IBM engineer, Rishi found his calling as an activist stepping up for complex people challenges that he couldn't ignore. Rishi is not a career politician and brings a fearless data-driven agenda to deliver results

SOURCE Rishi Kumar for Congress 2020


These press releases may also interest you

at 04:00
Modern Meadow, a leader in sustainable materials, has announced that David Williamson, PhD, will transition from president and chief operating officer (COO) to chief executive officer (CEO), effective October 14, 2024. Dr....

at 03:38
BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for oral presentation at ASN Kidney Week 2024 which will take place from October 23 to 27...

at 02:22
The following people have been appointed as members of SciBase Holding's nominating committee for the Annual General Meeting in 2025: Anders Bladh (Ribbskottet AB),Fredrik Mattsson (Ejendals AB)Dharminder Chahal (VanHerk Group),Jesper Høiland...

at 01:29
As global populations age and socio-demographic landscapes shift, the demand for healthcare services is rising dramatically. Combined with the persistent threat of communicable diseases, these factors are placing significant strain on healthcare...

at 01:05
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company's new Chief Executive Officer (CEO) and Chairman of the...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented positive 2-year data from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, October 8-12, 2024, assessing the efficacy and safety of Evrysdi®...



News published on and distributed by: